PLGA nanoparticles co-delivering MDR1 and BCL2 siRNA for overcoming resistance of paclitaxel and cisplatin in recurrent or advanced ovarian cancer
Crossref DOI link: https://doi.org/10.1038/s41598-018-25930-7
Published Online: 2018-05-14
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Risnayanti, Chitra
Jang, Yeong-Su
Lee, Jinju
Ahn, Hyung Jun
Text and Data Mining valid from 2018-05-14
Version of Record valid from 2018-05-14
Article History
Received: 29 November 2017
Accepted: 2 March 2018
First Online: 14 May 2018
Competing Interests
: The authors declare no competing interests.